Nuvectis Pharma, Inc. NVCT
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- +162.78%
- 1 year
- +232.33%
5D -1.93 (-9.13%)
- Market cap
- 682.28M
- EPS (ttm)
- -2.00
- Shares out
- 19.32M
- Forward P/E
- -4.77
- YTD return
- +162.78%
- 1-year return
- +232.33%
- 50-day average
- 6.43
- 200-day average
- 6.80
- Volume
- 156.98K
- Avg volume
- 205.84K
- Open
- 20.48
- Previous close
- 20.29
- Day's range
- 19.74 – 20.48
- 52-week range
- 5.77 – 29.28
- Beta
- 0.40
- Price target
- 22.00 (+10.9%)
Key statistics
- Enterprise value
- 70.16M
- Price / book
- 7.91
- Free cash flow
- -6.31M
- Total cash
- 17.17M
- Return on equity
- -140.00%
- Short % of float
- 13.99%
Fundamental scorecard
6 of 25 checks passed on NVCT’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.26 | -0.24 | +0.02 | +7.69% |
| Aug 6, 2024 | Jun 1, 2024 | -0.26 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.26 | -0.26 | 0.00 | 0.00% |
| May 7, 2024 | Mar 1, 2024 | -0.40 | -0.25 | +0.15 | +37.50% |
| May 7, 2024 | Mar 1, 2024 | -0.40 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.40 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 7, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Feb 10, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Jul 13, 2022 | Ladenburg Thalmann | init | — | Buy |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nuvectis.com
News
Your note
Sign in to keep a note on NVCT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENTSUR RON | Chief Executive Officer | Purchase | Nov 14, 2024 | 3,266,420 |
| CARSON MICHAEL J. | Officer | Sale | Nov 6, 2024 | 87,918 |
| HOBERMAN KENNETH | Director | Stock Award(Grant) | Jun 12, 2024 | 103,140 |
| KAPLAN MATTHEW L. | Director | Stock Award(Grant) | Jun 12, 2024 | 83,760 |
| MOSSERI MARLIO CHARLES | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 12, 2024 | 2,612,000 |
| OLIVIERO JAMES F III | Director | Stock Award(Grant) | Jun 12, 2024 | 57,828 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.56% | 301,138 | 1.38M | Sep 29, 2024 |
| Baldwin Wealth Partners LLC/MA | 0.90% | 174,130 | 797.51K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.41% | 79,716 | 365.10K | Sep 29, 2024 |
| Millennium Management Llc | 0.35% | 68,499 | 313.73K | Sep 29, 2024 |
| Iridian Asset Management LLC | 0.29% | 55,380 | 253.64K | Sep 29, 2024 |
| Gsa Capital Partners Llp | 0.26% | 50,129 | 229.59K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.20% | 231,040 | 1.06M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.30% | 57,030 | 261.20K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.19% | 37,447 | 171.51K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.11% | 21,218 | 97.18K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 13,310 | 60.96K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 8,938 | 40.94K | Oct 30, 2024 |
